Atlas Trials

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Clinical trial NCT04504916 · TERMINATED

Trial details

NCT number
NCT04504916
Sponsor
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Triple-negative Breast CancerNon-squamous Non-small-cell Lung CancerNSCLCEstrogen-receptor-positive Breast CancerProgesterone-receptor-positive Breast CancerEstrogen-receptor-negative Breast CancerER-negative Breast CancerProgesterone-receptor Negative Breast CancerPR-negative Breast CancerHER2-negative Breast CancerER-positive Breast CancerPR-positive Breast Cancer
Start date
2020-10-07
Primary completion
2023-06-12
Enrollment
102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.